drugset
drugset / Trial / NCT07229898

A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors

NCT07229898 ↗

Phase 1 Recruiting 48 enrolled Henan Genuine Biotech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

A phase Ⅰ clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of GEN-725 tablets in patients with advanced solid tumors.

Timeline

Start
2025-01-07
Primary completion
2026-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GEN-725 Unknown 4 mg Oral
Subject GEN-725 Unknown 6 mg Oral
Subject GEN-725 Unknown 8 mg Oral

Indications

cancer